PEMAZYRE DIN 02519933
Health Canada record
| Active ingredient(s) | PEMIGATINIB 4.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EN02 PEMIGATINIB |
| Original market date | 06-Jan-2022 |
| Current status date | 06-Jan-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Incyte Biosciences Technical Operations S.a.r.l. — licence , not currently licensed, last inspection rating C (2024-07-26).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEMIGATINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02519941 | PEMAZYRE | INCYTE CORPORATION | Tablet | PEMIGATINIB 9 MG | Marketed |
| 02519968 | PEMAZYRE | INCYTE CORPORATION | Tablet | PEMIGATINIB 13.5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26673 | 2021-09-17 | New Drug Submission (NDS) |
International API supply for PEMIGATINIB
1 active FDA Drug Master Files.
Request a quote for PEMAZYRE